----item----
version: 1
id: {61AC2427-2B88-48A9-972D-BB90CBFC85EA}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/02/18/VaxInnate snags $53m under BARDA contract extension
parent: {7236B4FE-DE6A-42E5-BF9D-A1048727BD42}
name: VaxInnate snags $53m under BARDA contract extension
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 68b64407-1d21-4f43-879a-396bcc3476e9

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 52

VaxInnate snags $53m under BARDA contract extension 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 51

VaxInnate snags $53m under BARDA contract extension
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1732

<p>US biotech VaxInnate is gaining an additional $53m under its February 2011 contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop vaccines against influenza. </p><p>Cranbury, New Jersey-based VaxInnate initially won a three-year $117.9m contract from BARDA, which had the potential to be extended for two additional years for a total of $196.6m (scripintelligence.com, <a href="http://www.scripintelligence.com/home/BARDA-bestows-215-million-flu-vaccine-contract-on-Novavax-VaxInnate-312018" target="_new">2 March 2011</a>).</p><p>The contract is part of Health and Human Services (HHS) national pandemic vaccine preparedness strategy, which includes the advanced development of new types of influenza vaccines, expanding and diversifying the domestic production process for those products and establishing and testing stockpiles of pre-pandemic vaccines.</p><p>VaxInnate said the additional $53m will be applied to the development its seasonal quadrivalent vaccine, VAX2012Q, and its pandemic influenza vaccine. </p><p>CEO Wayne Pisano said the company plans to advance VAX2012Q into a Phase II trial in adults 18-64 and its pandemic vaccine into Phase I and II studies. </p><p>VAX2012Q is comprised of four strains that are each fused to a flagellin protein, which acts as a toll-like receptor ligand. </p><p>In a Phase I study of 316 healthy adults 18-40, doses of VAX2012Q as low as 2mcg per component were shown to be immunogenic, with mean seroprotection rates exceeding 90% for each of the four vaccine components at the day 21 clinic visit. </p><p>The vaccine was generally well-tolerated, with mild to moderate arm pain the most commonly reported adverse event.</p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 202

<p>US biotech VaxInnate is gaining an additional $53m under its February 2011 contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop vaccines against influenza. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 51

VaxInnate snags $53m under BARDA contract extension
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150218T081259
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150218T081259
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150218T081259
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027852
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 52

VaxInnate snags $53m under BARDA contract extension 
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356717
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042256Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

68b64407-1d21-4f43-879a-396bcc3476e9
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042256Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
